IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Net Worth Advisory Group

Net Worth Advisory Group lowered its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.2% in the fourth quarter, Holdings Channel.com reports. The fund owned 1,002 shares of the company’s stock after selling 33 shares during the quarter. Net Worth Advisory Group’s holdings in IDEXX Laboratories were worth $414,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Insight Wealth Strategies LLC raised its holdings in IDEXX Laboratories by 230.5% during the fourth quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock worth $4,174,000 after purchasing an additional 7,041 shares during the last quarter. Larson Financial Group LLC increased its position in shares of IDEXX Laboratories by 17,238.5% in the third quarter. Larson Financial Group LLC now owns 2,254 shares of the company’s stock valued at $1,139,000 after buying an additional 2,241 shares in the last quarter. Quest Partners LLC boosted its position in shares of IDEXX Laboratories by 4,059.4% in the 3rd quarter. Quest Partners LLC now owns 2,870 shares of the company’s stock worth $1,450,000 after buying an additional 2,801 shares in the last quarter. Crystal Rock Capital Management boosted its position in shares of IDEXX Laboratories by 90.0% in the 3rd quarter. Crystal Rock Capital Management now owns 9,005 shares of the company’s stock worth $4,550,000 after buying an additional 4,265 shares in the last quarter. Finally, Victory Capital Management Inc. grew its stake in IDEXX Laboratories by 3.4% in the 3rd quarter. Victory Capital Management Inc. now owns 142,628 shares of the company’s stock valued at $72,059,000 after acquiring an additional 4,696 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.18% of the company’s stock.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $426.69 on Wednesday. The stock has a fifty day moving average price of $438.11 and a 200 day moving average price of $448.27. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $552.20. The firm has a market capitalization of $34.70 billion, a P/E ratio of 39.99, a PEG ratio of 3.41 and a beta of 1.39. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on IDXX shares. Morgan Stanley cut their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, March 7th. Barclays upped their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Leerink Partners began coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target for the company. Finally, Piper Sandler upped their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.